Volume 13, Issue 6, Pages (June 2006)

Slides:



Advertisements
Similar presentations
Phase I Study of H5.020CMV.PDGF-β to Treat Venous Leg Ulcer Disease
Advertisements

Volume 2, Issue 4, Pages (October 2000)
Molecular Diagnosis of Epstein-Barr Virus-Related Diseases
Robert J. Pitsch, MD, David J. Minion, MD, Margaret L
Volume 8, Issue 2, Pages (August 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
H. Wang, Y. Dong, J. Zhang, Z. Xu, G. Wang, C. A. Swain, Y. Zhang, Z
The Desmosomal Protein Desmoglein 1 Aids Recovery of Epidermal Differentiation after Acute UV Light Exposure  Jodi L. Johnson, Jennifer L. Koetsier, Anna.
Elaine E. Tseng, MD, Malcolm V. Brock, MD, Mary S. Lange, MA, Juan C
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
Volume 6, Issue 5, Pages (November 2002)
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Volume 9, Issue 5, Pages (May 2004)
Molecular Therapy - Nucleic Acids
Fibroblast growth factor-2 induced chondrocyte cluster formation in experimentally wounded articular cartilage is blocked by soluble Jagged-1  I.M. Khan,
Volume 10, Issue 4, Pages (October 2004)
Volume 12, Issue 5, Pages (November 2005)
Volume 4, Issue 1, Pages (July 2001)
Volume 14, Issue 1, Pages (July 2006)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Evolving Gene Therapy in Primary Immunodeficiency
Journal of Investigative Dermatology
Volume 13, Issue 6, Pages (June 2006)
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes  Lesley Wassef, Darren J. Kelly, Richard E. Gilbert 
Volume 9, Issue 6, Pages (June 2004)
Complete Cure of Persistent Virus Infections by Antiviral siRNAs
Phase I Study of H5.020CMV.PDGF-β to Treat Venous Leg Ulcer Disease
Keratinocyte growth factor accelerates compensatory growth in the remaining lung after trilobectomy in rats  Keitaro Matsumoto, MD, Takeshi Nagayasu,
Volume 12, Issue 5, Pages (November 2005)
Volume 26, Issue 2, Pages (February 2018)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Volume 3, Issue 6, Pages (June 2001)
Isolation (From a Basal Cell Carcinoma) of a Functionally Distinct Fibroblast-Like Cell Type that Overexpresses Ptch  Anthony J. Dicker, Magdalena M.
Heparin-Binding Epidermal-Growth-Factor-Like Growth Factor Activation of Keratinocyte ErbB Receptors Mediates Epidermal Hyperplasia, a Prominent Side-Effect.
Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury  Abigail K. Hanna, MD, Jonathan C. Fox, MD,
Davina A. Lewis, Simone F. Hengeltraub, Feng C. Gao, Megan A
Volume 2, Issue 3, Pages (September 2000)
Volume 3, Issue 2, Pages (February 2001)
FGF-7 Expression Enhances the Performance of Bioengineered Skin
Marcel Scheinman, MD, Enrico Ascher, MD, Gabriel S
Transduction of the E6 and E7 Genes of Epidermodysplasia-Verruciformis-Associated Human Papillomaviruses Alters Human Keratinocyte Growth and Differentiation.
Volume 13, Issue 2, Pages (February 2006)
Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 
Volume 9, Issue 6, Pages (June 2004)
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Volume 3, Issue 2, Pages (February 2001)
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Volume 4, Issue 1, Pages (July 2001)
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Volume 12, Issue 2, Pages (August 2005)
Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell 
Volume 13, Issue 3, Pages (March 2006)
Volume 8, Issue 2, Pages (August 2003)
Effect of Tenascin-C Deficiency on Chemically Induced Dermatitis in the Mouse  Yoh-ichi Koyama, Masashi Kusubata, Atsushi Yoshiki, Noriko Hiraiwa, Tomoo.
Volume 13, Issue 3, Pages (March 2006)
Volume 26, Issue 1, Pages (January 2018)
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 3, Issue 5, Pages (May 2001)
Volume 15, Issue 7, Pages (July 2007)
Volume 12, Issue 6, Pages (December 2005)
Volume 9, Issue 3, Pages (March 2004)
Rachel Maddox Schek, Scott J Hollister, Paul H Krebsbach 
Volume 11, Issue 1, Pages (January 2005)
Volume 7, Issue 1, Pages (January 2003)
Volume 16, Issue 10, Pages (October 2008)
Shirley Wong, Roderick A. Slavcev
Molecular Therapy - Nucleic Acids
Delivery of a Retroviral Vector Expressing Human β-Glucuronidase to the Liver and Spleen Decreases Lysosomal Storage in Mucopolysaccharidosis VII Mice 
Presentation transcript:

Volume 13, Issue 6, Pages 1142-1148 (June 2006) A Protease Inhibitor Specifically Inhibits Growth of HPV-Infected Keratinocytes  David A. Drubin, Margaret E. McLaughlin-Drubin, Gary A. Clawson, Craig Meyers  Molecular Therapy  Volume 13, Issue 6, Pages 1142-1148 (June 2006) DOI: 10.1016/j.ymthe.2006.02.005 Copyright © 2006 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Effects of AAPFcmk, GRcmk, and/or DMSO on AWCA organotypic raft cultures. AWCA cells, which contain integrated HPV18, were grown in organotypic raft culture. Treatments were made every other day with feeding for 10 days, and the raft cultures were harvested, fixed, sectioned, and stained with hematoxylin and eosin. Rafts were either (A) untreated or treated with (B) 0.25% DMSO solvent control, (C) 10 μM AAPFcmk, (D) 25 μM AAPFcmk, (E) 50 μM AAPFcmk, (F) 10 μM GRcmk, (G) 25 μM GRcmk, or (H) 50 μM GRcmk. Of note is the significant attenuation of the raft cultures by the higher concentration treatments (D and E) of AAPFcmk. Images are at 20× original magnification. Molecular Therapy 2006 13, 1142-1148DOI: (10.1016/j.ymthe.2006.02.005) Copyright © 2006 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Effects of AAPFcmk, GRcmk, and DMSO on CIN-612 9E organotypic raft cultures. CIN-612 9E cells, which contain episomal high-risk HPV31b, were grown in organotypic raft culture. Treatments were made every other day with feeding for 10 days, and the rafts were harvested, fixed, sectioned, and stained with hematoxylin and eosin. Rafts were either (A) untreated or treated with (B) 0.25% DMSO solvent control, (C) 10 μM AAPFcmk, (D) 25 μM AAPFcmk, (E) 50 μM AAPFcmk, (F) 10 μM GRcmk, (G) 25 μM GRcmk, or (H) 50 μM GRcmk. Of note is the significant raft thinning by the higher concentration treatments (D and E) of AAPFcmk. Images are at 20× original magnification. Molecular Therapy 2006 13, 1142-1148DOI: (10.1016/j.ymthe.2006.02.005) Copyright © 2006 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Effects of AAPFcmk, GRcmk, and/or DMSO on HFK organotypic raft cultures. Primary HFKs were grown in organotypic raft culture. Treatments were made every other day with feeding for 10 days, and the rafts were harvested, fixed, sectioned, and stained with hematoxylin and eosin. Rafts were either (A) untreated or treated with (B) 0.25% DMSO solvent control, (C) 10 μM AAPFcmk, (D) 25 μM AAPFcmk, (E) 50 μM AAPFcmk, (F) 10 μM GRcmk, (G) 25 μM GRcmk, or (H) 50 μM GRcmk. Notable is the lack of thinning effects in (D) and (E) that is observed in HPV-containing cells (Figs. 1 and 2). Images are at 20× original magnification. Molecular Therapy 2006 13, 1142-1148DOI: (10.1016/j.ymthe.2006.02.005) Copyright © 2006 The American Society of Gene Therapy Terms and Conditions

FIG. 4 C33A organotypic raft cultures treated with AAPFcmk, GRcmk, and DMSO. C33A cells, which are derived from a non-HPV-containing carcinoma, were grown as organotypic raft cultures. Treatments were made every other day with feeding for 10 days, and the rafts were harvested, fixed, sectioned, and stained with hematoxylin and eosin. Rafts were either (A) untreated or treated with (B) 0.25% DMSO solvent control, (C) 25 μM AAPFcmk, (D) 50 μM AAPFcmk, (E) 25 μM GRcmk, or (F) 50 μM GRcmk. Of note is the lack of effect of AAPFcmk treatment on the raft growth (C and D). Images are at 20× original magnification. Molecular Therapy 2006 13, 1142-1148DOI: (10.1016/j.ymthe.2006.02.005) Copyright © 2006 The American Society of Gene Therapy Terms and Conditions

FIG. 5 Effects of AAPFcmk on HPV genome copy number in the CIN-612 9E cell line. CIN-612 9E cells were grown in organotypic raft culture. Treatments of 0.25% DMSO and AAPFcmk and GRcmk as labeled at the top were applied to the raft cultures every other day with feeding over the course of 10 days. DNA was harvested and digested with either a noncutter of the HPV31 genome, BamHI (B), or a single-cutter, HindIII (H), and a Southern blot was performed as described with a 32P-labeled probe for the HPV31 genome; controls with 100, 10, or 1 copy number per cell were included. Form II DNA (nicked supercoiled) and Form I DNA (supercoiled) episomal HPV31 bands are observed in the uncut lanes and Form III DNA (linear) is seen in the single-cut lanes. Note the dose-dependent decrease in episomal HPV DNA; it is reduced by ∼50% with 25 μM AAPFcmk and by ∼75% with 50 μM AAPFcmk. Molecular Therapy 2006 13, 1142-1148DOI: (10.1016/j.ymthe.2006.02.005) Copyright © 2006 The American Society of Gene Therapy Terms and Conditions